Market Overview:
The global insomnia therapeutics drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of insomnia, rising awareness about available treatment options, and growing demand for prescription and over-the-counter (OTC) drugs for the treatment of insomnia. Based on type, the global insomnia therapeutics drugs market is segmented into benzodiazepines, nonbenzodiazepines, antidepressants, orexin antagonists, melatonin antagonists, and others. Benzodiazepines are expected to account for the largest share of this market in 2018 owing to their high efficacy and safety profile. However, nonbenzodiazepine drugs are projected to grow at the highest CAGR during the forecast period due to their better tolerability profile as compared with benzodiazepine drugs. Based on application, this market is segmented into prescription and OTC Drugs.
Product Definition:
Insomnia Therapeutics Drugs are used to treat insomnia, which is a sleep disorder characterized by difficulty falling and/or staying asleep. Insomnia can be caused by many factors, including stress, anxiety, pain, medications, and health conditions. Insomnia Therapeutics Drugs work by increasing the amount of time spent in deep sleep and reducing the number of awakenings during the night.
Benzodiazepines:
Benzodiazepines are generally prescribed for the treatment of insomnia, anxiety, and stress. They work by enhancing the action of a natural brain chemical called gamma-aminobutyric acid (GABA). Benzodiazepines can cause drowsiness and may be habit forming.
The global benzodiazepine market was valued at USD 7.8 billion in 2015.
Nonbenzodiazepines:
Nonbenzodiazepines are a class of drug that is used for the treatment of insomnia. They are also used to treat anxiety, panic disorders, agoraphobia, and other sleep disorders.
Application Insights:
The prescription insomnia therapeutics drugs market is anticipated to reach USD 281.1 million by 2030. Growing demand for sleeping pills among patients suffering from anxiety and stress-related disorders is expected to drive the growth of this segment in the near future. The growing prevalence of mental disorders, such as depression, and increasing awareness about treatment are some factors that may hinder the growth during the forecast period but should not hinder overall industry growth by 2030.
Insomnia OTC products are available in various forms including tablets, liquids, gels and patches; however, only a few of these products have been proven effective against sleeplessness or other associated symptoms such as daytime sleepiness or fatigue during clinical trials conducted thus far.
Regional Analysis:
North America dominated the global insomnia therapeutics market in 2017. The presence of a large number of manufacturers, along with an increase in the prevalence of sleep disorders, is one major factor responsible for its largest share. In addition, rising awareness about sleep disorders and their treatment options is also expected to drive growth during the forecast period.
Asia Pacific region is anticipated to witness lucrative growth over the forecast period owing to factors such as increasing geriatric population and lifestyle changes that are resulting into insomnia patients; growing economy coupled with high disposable income which leads towards increased consumption of alcohol or drugs that may lead towards sleeping disorder; rise in stress due to work pressure or study etc.; among others’ are some major driving factors for this region.
Growth Factors:
- Increasing prevalence of insomnia and other sleep disorders
- Growing awareness about the benefits of Insomnia Therapeutics Drugs
- Rising demand for better treatment options for insomnia and other sleep disorders
- Technological advancements in Insomnia Therapeutics Drugs industry
- Increasing investments by pharmaceutical companies in research and development of new drugs for the treatment of insomnia and other sleep disorders
Scope Of The Report
Report Attributes
Report Details
Report Title
Insomnia Therapeutics Drugs Market Research Report
By Type
Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin Antagonists, Others
By Application
Prescription, Over-the-Counter (OTC)
By Companies
Takeda Pharmaceutical Company Ltd., Vanda Pharmaceuticals, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Sumitomo Dainippon Pharma Co., Ltd, Sanofi, Paratek Pharmaceuticals Inc., Ebb Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Insomnia Therapeutics Drugs Market Report Segments:
The global Insomnia Therapeutics Drugs market is segmented on the basis of:
Types
Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin Antagonists, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Prescription, Over-the-Counter (OTC)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Takeda Pharmaceutical Company Ltd.
- Vanda Pharmaceuticals
- Merck & Co., Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Sumitomo Dainippon Pharma Co., Ltd
- Sanofi
- Paratek Pharmaceuticals Inc.
- Ebb Therapeutics
Highlights of The Insomnia Therapeutics Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Benzodiazepines
- Nonbenzodiazepines
- Antidepressants
- Orexin Antagonists
- Melatonin Antagonists
- Others
- By Application:
- Prescription
- Over-the-Counter (OTC)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Insomnia Therapeutics Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Insomnia Therapeutics drugs are medications used to treat insomnia. These medications can be prescribed by a doctor, and they work by helping people fall asleep or stay asleep.
Some of the key players operating in the insomnia therapeutics drugs market are Takeda Pharmaceutical Company Ltd., Vanda Pharmaceuticals, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Sumitomo Dainippon Pharma Co., Ltd, Sanofi, Paratek Pharmaceuticals Inc., Ebb Therapeutics.
The insomnia therapeutics drugs market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Insomnia Therapeutics Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Insomnia Therapeutics Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Insomnia Therapeutics Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Insomnia Therapeutics Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Insomnia Therapeutics Drugs Market Size & Forecast, 2018-2028
4.5.1 Insomnia Therapeutics Drugs Market Size and Y-o-Y Growth
4.5.2 Insomnia Therapeutics Drugs Market Absolute $ Opportunity
Chapter 5 Global Insomnia Therapeutics Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Insomnia Therapeutics Drugs Market Size Forecast by Type
5.2.1 Benzodiazepines
5.2.2 Nonbenzodiazepines
5.2.3 Antidepressants
5.2.4 Orexin Antagonists
5.2.5 Melatonin Antagonists
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Insomnia Therapeutics Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Insomnia Therapeutics Drugs Market Size Forecast by Applications
6.2.1 Prescription
6.2.2 Over-the-Counter (OTC)
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Insomnia Therapeutics Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Insomnia Therapeutics Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Insomnia Therapeutics Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Insomnia Therapeutics Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Insomnia Therapeutics Drugs Market Size Forecast by Type
9.6.1 Benzodiazepines
9.6.2 Nonbenzodiazepines
9.6.3 Antidepressants
9.6.4 Orexin Antagonists
9.6.5 Melatonin Antagonists
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Insomnia Therapeutics Drugs Market Size Forecast by Applications
9.10.1 Prescription
9.10.2 Over-the-Counter (OTC)
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Insomnia Therapeutics Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Insomnia Therapeutics Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Insomnia Therapeutics Drugs Market Size Forecast by Type
10.6.1 Benzodiazepines
10.6.2 Nonbenzodiazepines
10.6.3 Antidepressants
10.6.4 Orexin Antagonists
10.6.5 Melatonin Antagonists
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Insomnia Therapeutics Drugs Market Size Forecast by Applications
10.10.1 Prescription
10.10.2 Over-the-Counter (OTC)
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Insomnia Therapeutics Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Insomnia Therapeutics Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Insomnia Therapeutics Drugs Market Size Forecast by Type
11.6.1 Benzodiazepines
11.6.2 Nonbenzodiazepines
11.6.3 Antidepressants
11.6.4 Orexin Antagonists
11.6.5 Melatonin Antagonists
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Insomnia Therapeutics Drugs Market Size Forecast by Applications
11.10.1 Prescription
11.10.2 Over-the-Counter (OTC)
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Insomnia Therapeutics Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Insomnia Therapeutics Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Insomnia Therapeutics Drugs Market Size Forecast by Type
12.6.1 Benzodiazepines
12.6.2 Nonbenzodiazepines
12.6.3 Antidepressants
12.6.4 Orexin Antagonists
12.6.5 Melatonin Antagonists
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Insomnia Therapeutics Drugs Market Size Forecast by Applications
12.10.1 Prescription
12.10.2 Over-the-Counter (OTC)
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Insomnia Therapeutics Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Insomnia Therapeutics Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Insomnia Therapeutics Drugs Market Size Forecast by Type
13.6.1 Benzodiazepines
13.6.2 Nonbenzodiazepines
13.6.3 Antidepressants
13.6.4 Orexin Antagonists
13.6.5 Melatonin Antagonists
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Insomnia Therapeutics Drugs Market Size Forecast by Applications
13.10.1 Prescription
13.10.2 Over-the-Counter (OTC)
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Insomnia Therapeutics Drugs Market: Competitive Dashboard
14.2 Global Insomnia Therapeutics Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Takeda Pharmaceutical Company Ltd.
14.3.2 Vanda Pharmaceuticals
14.3.3 Merck & Co., Inc.
14.3.4 Pfizer Inc.
14.3.5 Teva Pharmaceutical Industries Ltd.
14.3.6 Mylan N.V.
14.3.7 Sumitomo Dainippon Pharma Co., Ltd
14.3.8 Sanofi
14.3.9 Paratek Pharmaceuticals Inc.
14.3.10 Ebb Therapeutics
